Get started
Author

María Julia Montoro

Observed names: Julia Montoro, Julia Montoro Gomez, Julia Montoro Gómez, Julia Montoro-Gómez, Julía Montoro, Maria Julia Montoro, Maria Julia Montoro Gómez, Montoro Gómez, Julia, Montoro Gómez, Maria Julia, Montoro, Maria Julia
Observed institutions: Universitat Autònoma de Barcelona, Columbia University Irving Medical Center, Hospital de Sant Pau, Bellvitge University Hospital, Vall d'Hebron Institut de Recerca, Hospital Clínic de Barcelona, Vall d'Hebron Hospital Universitari, Hospital Del Mar, Hospital Universitario Central de Asturias, Hospital del Mar Research Institute, S2 Grupo (Spain), Vall d'Hebron Institute of Oncology, Columbia University
ORCID: 0000-0001-9532-7417
Observed ORCID: 0000-0001-9532-7417
OpenAlex ID: A5003379992
Cell free circulating tumor DNA in cerebrospinal fluid detects and monitors central nervous system involvement of B-cell lymphomas
2020 · Sabela Bobillo, Marta Crespo, et al. · Haematologica · 130
PDF
Uncovering perturbations in human hematopoiesis associated with healthy aging and myeloid malignancies at single-cell resolution
2023 · Marina Ainciburu, Teresa Ezponda, et al. · eLife · 67
Complex, Not Monosomal, Karyotype Is the Cytogenetic Marker of Poorest Prognosis in Patients With Primary Myelodysplastic Syndrome
2013 · David Valcárcel, Vera Ademà, et al. · Journal of Clinical Oncology · 67
PDF
Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study
2021 · Lisa Pleyer, Michael Leisch, et al. · The Lancet Haematology · 54
Autoimmune disorders are common in myelodysplastic syndrome patients and confer an adverse impact on outcomes
2018 · Julia Montoro, Laura Gallur, et al. · Annals of Hematology · 49
Influence of TP53 gene mutations and their allelic status in myelodysplastic syndromes with isolated 5q deletion
2024 · Maria Julia Montoro, Laura Palomo, et al. · Blood · 31
Use of newer prognostic indices for patients with myelodysplastic syndromes in the low and intermediate-1 risk categories: a population-based study
2015 · David Valcárcel, Guillermo Sanz, et al. · The Lancet Haematology · 28
Trisomy 8, a Cytogenetic Abnormality in Myelodysplastic Syndromes, Is Constitutional or Not?
2015 · Sílvia Saumell, Francesc Solé, et al. · PLoS ONE · 26
PDF
The transcription factor DDIT3 is a potential driver of dyserythropoiesis in myelodysplastic syndromes
2022 · Nerea Berastegui, Marina Ainciburu, et al. · Nature Communications · 24
PDF
Considering Bone Marrow Blasts From Nonerythroid Cellularity Improves the Prognostic Evaluation of Myelodysplastic Syndromes
2016 · Leonor Arenillas, Xavier Calvo, et al. · Journal of Clinical Oncology · 24
Machine Learning Improves Risk Stratification in Myelodysplastic Neoplasms: An Analysis of the Spanish Group of Myelodysplastic Syndromes
2023 · Adrian Mosquera Orgueira, Manuel Mateo Perez Encinas, et al. · HemaSphere · 19
Improving Treatment for Myelodysplastic Syndromes Patients
2018 · Julia Montoro, Aslihan Yerlikaya, et al. · Current Treatment Options in Oncology · 14
Single-cell transcriptional profile of CD34+ hematopoietic progenitor cells from del(5q) myelodysplastic syndromes and impact of lenalidomide
2024 · Guillermo Serrano, Nerea Berastegui, et al. · Nature Communications · 13
Erythroleukemia shares biological features and outcome with myelodysplastic syndromes with excess blasts: a rationale for its inclusion into future classifications of myelodysplastic syndromes
2016 · Xavier Calvo, Leonor Arenillas, et al. · Modern Pathology · 13
PDF
Enumerating bone marrow blasts from nonerythroid cellularity improves outcome prediction in myelodysplastic syndromes and permits a better definition of the intermediate risk category of the Revised International Prognostic Scoring System (IPSS‐R)
2017 · Xavier Calvo, Leonor Arenillas, et al. · American Journal of Hematology · 12
PDF
DDX41-mutant myeloid neoplasms defy current prognostic schemes and require a dedicated risk scoring system: a multicenter, retrospective study
2025 · Carmelo Gurnari, Hideki Makishima, et al. · Leukemia · 11
Validation of the Artificial Intelligence Prognostic Scoring System for Myelodysplastic Syndromes in chronic myelomonocytic leukaemia: A novel approach for improved risk stratification
2024 · Adrian Mosquera Orgueira, Manuel Mateo Perez Encinas, et al. · British Journal of Haematology · 7
Study of Causes of Death in Patients with Myelodysplastic Syndrome: A Single Institution Experience
2011 · Julia Montoro, Teresa Vallespi, et al. · Blood · 7
IPSS-M Applicability and Clinical Impact in Decision-Making Process in Real-Life Clinical Practice
2022 · Sandra Novoa Jáuregui, Laura Palomo, et al. · Blood · 6
Acute Renal Failure Due to Membranoproliferative Glomerulonephritis and Kidney Tumoral Infiltration in a Patient with Mantle Cell Lymphoma
2015 · Julia Montoro · Hematology & Transfusion International Journal · 6
PDF
Effects of the Therapeutic Armamentarium on Survival and Time to Next Treatment in CMML Subtypes: An International Analysis of 950 Cases Coordinated By the AGMT Study Group
2019 · Lisa Pleyer, Michael Leisch, et al. · Blood · 5
Supervised Machine Learning Improves Risk Stratification in Newly Diagnosed Myelodysplastic Syndromes: An Analysis of the Spanish Group of Myelodysplastic Syndromes
2022 · Adrian Mosquera Orgueira, Manuel Perez Encinas, et al. · Blood · 4
Artificial Intelligence Models for Risk Stratification and Prognosis in AML-NOS
2024 · Álvaro López-Caro, Ana Mendoza, et al. · Blood · 3
PDF
Prevalence, Dynamics and Clinical Significance of Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Newly Diagnosed Cancer Patients
2023 · Ana Pérez González, Clàudia Pellín Jou, et al. · Blood · 3
A Revised International Prognostic Scoring System of 3.5 Points Stratifies Patients with Myelodysplastic Syndromes into 2 Risk Categories
2020 · Maria Julia Montoro, Margarita Ortega, et al. · Blood · 3
Works count: 131
Citation count: 670
H-index: 13
I10-index: 16
Year
Topic
Type